$SBFM
Sunshine Biopharma Inc. Stock $sbfm

$sbfm Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000168316823002128 Filed on April 04, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$4.894M	$3.940M	$4.346M
YoY Change	3890.26%	4528.57%	1802.38%
Cost Of Revenue	$3.066M	$2.449M	$2.649M
YoY Change	5022.69%	3895.3%	2148.18%
Gross Profit	$1.828M	$1.491M	$1.697M
YoY Change	2811.02%	6157.32%	1433.97%
Gross Profit Margin	37.35%	37.85%	39.04%
Selling, General & Admin	$3.785M	$6.305M	$29.28M
YoY Change	310.79%	2915.46%	1469.07%
% of Gross Profit	207.04%	422.82%	1725.56%
Research & Development	$432.9K	$41.76K	$811.9K
YoY Change	19.71%	-54.21%	20.77%
% of Gross Profit	23.68%	2.8%	47.85%
Depreciation & Amortization	$34.71K	$18.97K	$25.16K
YoY Change	1016.08%	496.54%	97.49%
% of Gross Profit	1.9%	1.27%	1.48%
Operating Expenses	$4.218M	$6.528M	$30.09M
YoY Change	227.95%	2051.19%	1079.56%
Operating Profit	-$1.829M	-$5.037M	-$27.00M
YoY Change	49.5%	1701.27%	1006.53%
Interest Expense	$41.08K	$84.60K	$39.41K
YoY Change	-419.15%	-394.77%	-112.28%
% of Operating Profit
Other Income/Expense, Net	$172.8K		$489.6K
YoY Change	-1442.82%
Pretax Income	-$1.656M	-$23.28M	-$26.51M
YoY Change	33.97%	-3589.48%	113.17%
Income Tax	$46.27K	$233.3K	$233.3K
% Of Pretax Income
Net Earnings	-$1.702M	-$23.51M	-$26.74M
YoY Change	37.71%	-3624.45%	115.05%
Net Earnings / Revenue	-34.79%	-596.78%	-615.44%
Basic Earnings Per Share	-$7.73		-$1.76
Diluted Earnings Per Share	-$0.08	-$1.05	-$1.76
COMMON SHARES
Basic Shares Outstanding	22.59M shares	22.59M shares	15.18M shares
Diluted Shares Outstanding	22.04M shares		15.18M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.29M	$21.83M	$21.83M
YoY Change	46.42%	967.22%	967.22%
Cash & Equivalents	$19.29M	$21.83M	$21.83M
Short-Term Investments
Other Short-Term Assets	$152.3K	$283.8K	$283.8K
YoY Change	229.42%	662.49%	662.49%
Inventory	$3.710M	$3.290M	$3.290M
Prepaid Expenses	$152.3K	$283.8K
Receivables	$1.790M	$1.912M	$1.912M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$24.95M	$27.31M	$27.31M
YoY Change	86.1%	1143.83%	1143.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$368.0K	$394.2K	$1.155M
YoY Change	9147.04%	5483.47%	16254.96%
Goodwill		$0.00
YoY Change
Intangibles	$948.2K	$776.9K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.044M	$1.932M	$1.932M
YoY Change	51396.25%	27254.68%	27258.64%
TOTAL ASSETS
Total Short-Term Assets	$24.95M	$27.31M	$27.31M
Total Long-Term Assets	$2.044M	$1.932M	$1.932M
Total Assets	$26.99M	$29.24M	$29.24M
YoY Change	101.29%	1227.52%	1227.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.736M	$2.803M	$2.803M
YoY Change	2773.21%	6426.93%	6427.25%
Accrued Expenses	$121.3K	$123.0K	$123.0K
YoY Change		154.77%	154.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$6.906M	$6.931M	$6.931M
YoY Change	7151.6%	7497.38%	7497.29%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$613.1K	$642.2K	$642.2K
YoY Change
Total Long-Term Liabilities	$656.2K	$685.3K	$642.2K
YoY Change		-63.93%	-66.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.906M	$6.931M	$6.931M
Total Long-Term Liabilities	$656.2K	$685.3K	$642.2K
Total Liabilities	$7.562M	$7.616M	$7.616M
YoY Change	7840.64%	282.49%	282.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$61.10M	-$59.40M
YoY Change		81.9%
Common Stock	$22.14K	$22.59K
YoY Change		771.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.43M	$21.63M	$21.63M
YoY Change
Total Liabilities & Shareholders Equity	$26.99M	$29.24M	$29.24M
YoY Change	101.29%	1227.52%	1227.52%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.702M	-$23.51M	-$26.74M
YoY Change	37.71%	-3624.45%	115.05%
Depreciation, Depletion And Amortization	$34.71K	$18.97K	$25.16K
YoY Change	1016.08%	496.54%	97.49%
Cash From Operating Activities	-$1.850M	-$2.247M	-$5.248M
YoY Change	41.86%	619.81%	186.93%
INVESTING ACTIVITIES
Capital Expenditures	$178.4K	$305.0K	$194.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$32.09K	-$14.31M	-$14.31M
YoY Change
Cash From Investing Activities	-$146.3K	-$14.62M	-$14.62M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$30.37M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$538.3K	-2.096M	$39.47M
YoY Change	-104.33%	8759.89%	1258.67%
NET CHANGE
Cash From Operating Activities	-$1.850M	-2.247M	-$5.248M
Cash From Investing Activities	-$146.3K	-14.62M	-$14.62M
Cash From Financing Activities	-$538.3K	-2.096M	$39.47M
Net Change In Cash	-$2.535M	-18.96M	$19.60M
YoY Change	-122.77%	5547.39%	1722.08%
FREE CASH FLOW
Cash From Operating Activities	-$1.850M	-$2.247M	-$5.248M
Capital Expenditures	$178.4K	$305.0K	$194.0K
Free Cash Flow	-$2.029M	-$2.552M	-$5.442M
YoY Change		717.54%	197.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001402328
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	SBFM	Debt Release DebtRelease		usd
CY2022	SBFM	Fractional Shares Issued For Reverse Stock Split FractionalSharesIssuedForReverseStockSplit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41282
CY2022	dei	Entity Registrant Name EntityRegistrantName	SUNSHINE BIOPHARMA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5566275
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	6500 Trans-Canada Highway
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	4th Floor
CY2022	dei	Entity Address Address Line3 EntityAddressAddressLine3	Pointe-Claire
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Quebec
CY2022	dei	Entity Address Country EntityAddressCountry	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	H9R 0A5
CY2022	dei	City Area Code CityAreaCode	(514)
CY2022	dei	Local Phone Number LocalPhoneNumber	426-6161
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	19949542	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22585632	shares
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Location AuditorLocation	Lakewood
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21826437	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2045167	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1912153	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7798	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3289945	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	105650	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	283799	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29625	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	7590	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27312334	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2195830	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	394249	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7061	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	776856	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	760409	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q4	us-gaap	Assets Assets	29243848	usd
CY2021Q4	us-gaap	Assets Assets	2202891	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2802796	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	42942	usd
CY2022Q4	SBFM	Earnout Payable EarnoutPayable	3632000	usd
CY2021Q4	SBFM	Earnout Payable EarnoutPayable	0	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	48287	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	373191	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123026	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6931014	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	91229	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1900000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	642232	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	43032	usd
CY2021Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	685264	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1900000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7616278	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1991229	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	100000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2550730	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22585632	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2591240	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22585	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2591	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80841752	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32787384	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	161847	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23139	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59399614	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32655174	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	211662	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29243848	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2202891	usd
CY2022	us-gaap	Revenues Revenues	4345603	usd
CY2021	us-gaap	Revenues Revenues	228426	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	2649028	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	117830	usd
CY2022	us-gaap	Gross Profit GrossProfit	1696575	usd
CY2021	us-gaap	Gross Profit GrossProfit	110596	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	341139	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	118423	usd
CY2022	SBFM	Consulting Expense ConsultingExpense	842894	usd
CY2021	SBFM	Consulting Expense ConsultingExpense	50873	usd
CY2022	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	300000	usd
CY2021	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	0	usd
CY2022	us-gaap	Legal Fees LegalFees	565265	usd
CY2021	us-gaap	Legal Fees LegalFees	232616	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	578085	usd
CY2021	us-gaap	Marketing Expense MarketingExpense	0	usd
CY2022	SBFM	Office Expense OfficeExpense	796007	usd
CY2021	SBFM	Office Expense OfficeExpense	248561	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	811858	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	672209	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	6054962	usd
CY2021	us-gaap	Salaries And Wages SalariesAndWages	1215307	usd
CY2022	SBFM	Other Taxes OtherTaxes	55233	usd
CY2021	SBFM	Other Taxes OtherTaxes	0	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25163	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12741	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18326719	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28697325	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-27000750	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2440134	usd
CY2022	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	-0	usd
CY2021	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	9726485	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-476	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	50	usd
CY2022	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	518650	usd
CY2021	us-gaap	Interest Income Debt Securities Operating InterestIncomeDebtSecuritiesOperating	0	usd
CY2022	us-gaap	Interest Expense InterestExpense	39412	usd
CY2021	us-gaap	Interest Expense InterestExpense	328818	usd
CY2022	SBFM	Debt Forgiveness DebtForgiveness	10852	usd
CY2021	SBFM	Debt Forgiveness DebtForgiveness	51031	usd
CY2022	SBFM	Interest Forgiveness InterestForgiveness	-0	usd
CY2021	SBFM	Interest Forgiveness InterestForgiveness	-7909	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	489614	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9996313	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26511136	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12436447	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	233304	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26744440	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12436447	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	184986	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-20268	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26559454	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12456715	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.76
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.76
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15180868	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2612061	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26744440	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12436447	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25163	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12741	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	18326719	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-548	usd
CY2021	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	50	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	918000	usd
CY2022	SBFM	Debt Release DebtRelease	10852	usd
CY2022	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
CY2021	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	9726485	usd
CY2022	SBFM	Gain On Interest And Debt Forgiveness GainOnInterestAndDebtForgiveness	-0	usd
CY2021	SBFM	Gain On Interest And Debt Forgiveness GainOnInterestAndDebtForgiveness	-58940	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	524486	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5882	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-42983	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	81879	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1075547	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1075	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-82846	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	26847	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3359141	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-18156	usd
CY2022	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	3628	usd
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	238679	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-48287	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	23967	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5248358	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1829128	usd
CY2022	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	33379	usd
CY2021	SBFM	Reduction In Right Of Use Asset ReductionInRightOfUseAsset	0	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	14346637	usd
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	-0	usd
CY2022	SBFM	Cash Given From Acquisition CashGivenFromAcquisition	1135	usd
CY2021	SBFM	Cash Given From Acquisition CashGivenFromAcquisition	-0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	111015	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	193982	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14619390	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30367185	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13193177	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	99000	usd
CY2021	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	-0	usd
CY2022	SBFM	Reduction In Lease Liability ReductionInLeaseLiability	31924	usd
CY2021	SBFM	Reduction In Lease Liability ReductionInLeaseLiability	-0	usd
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	2064331	usd
CY2021	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	-0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3318500	usd
CY2022	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	0	usd
CY2021	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	61500	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1900000	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	475325	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39465107	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2904675	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2045167	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	989888	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	19597359	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	184986	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-20268	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21826437	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2045167	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	48287	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	38117	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	SBFM	Stock Issued For Note Conversions StockIssuedForNoteConversions	0	usd
CY2021	SBFM	Stock Issued For Note Conversions StockIssuedForNoteConversions	12705214	usd
CY2022	SBFM	Stock Issued For Acquisition Of Norma Pharma Inc. StockIssuedForAcquisitionOfNormaPharmaInc.	4514000	usd
CY2021	SBFM	Stock Issued For Acquisition Of Norma Pharma Inc. StockIssuedForAcquisitionOfNormaPharmaInc.	0	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-954837	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	12705214	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	918000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12456715	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	211662	usd
CY2022	SBFM	Common Stock And Warrants Issued In Offerings CommonStockAndWarrantsIssuedInOfferings	30367185	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13193177	usd
CY2022	SBFM	Preferred Stock Purchased From Related Party Value PreferredStockPurchasedFromRelatedPartyValue	99000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	4514000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26559454	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21627570	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zLxsZbG4Yy4a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zYRkQkOZ1Z51" style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><i>USE OF ESTIMATES</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">The preparation of financial statements in conformity with US Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21826437	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2045167	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zGvVtbk4oH0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_znlPIOhEAr99" style="font-family: Arial, Helvetica, Sans-Serif; color: #00487F"><i>CONCENTRATION OF CREDIT RISKS</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents and trade receivables. The Company places its cash equivalents with high credit quality financial institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif"> </span></p>
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	1358121	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	3181916	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	659571	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment	210503	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	1105093	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	6515204	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	5981286	usd
CY2022Q4	us-gaap	Business Combination Assets And Liabilities Arising From Contingencies Amount Recognized BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized	533918	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	18326719	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	18860637	usd
CY2022	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.74
CY2021	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-4.70
CY2022	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	15056097	shares
CY2021	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	2612061	shares
CY2022	SBFM	Total Income Tax Expense Benefit TotalIncomeTaxExpenseBenefit	143484	usd
CY2022Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 200 reverse split
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2021	SBFM	Stock Issued During Period Shares StockIssuedDuringPeriodShares	859114	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22585632	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2591240	shares
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-26744440	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12436447	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15180868	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2612061	shares
CY2022	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2021	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15180868	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2612061	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.76
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	139856	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3628	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4323025	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	98957	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1021230	usd
CY2022Q4	SBFM	Deferred Tax Assets Research And Development DeferredTaxAssetsResearchAndDevelopment	90000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	161719	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	202793	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5596431	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	301293	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	-0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	142817	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	201508	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	344325	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	43032	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	0	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	1900000	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	48287	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	48287	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	760409	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	123026	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	642232	usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P7Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	123026	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	115879	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	116066	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	109934	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	103547	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	196807	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1785000	usd
CY2021	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	297307	usd
CY2022	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	300000	usd
CY2021	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	0	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001683168-23-002128-index-headers.html	Edgar Link	pending
0001683168-23-002128-index.html	Edgar Link	pending
0001683168-23-002128.txt	Edgar Link	pending
0001683168-23-002128-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbfm-20221231.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
sunshine_ex2100.htm	Edgar Link	pending
sunshine_ex2301.htm	Edgar Link	pending
sunshine_ex3101.htm	Edgar Link	pending
sunshine_ex3102.htm	Edgar Link	pending
sunshine_ex3201.htm	Edgar Link	pending
sunshine_i10k-123122.htm	Edgar Link	pending
sbfm-20221231_cal.xml	Edgar Link	unprocessable
sbfm-20221231_lab.xml	Edgar Link	unprocessable
sbfm-20221231_def.xml	Edgar Link	unprocessable
sbfm-20221231_pre.xml	Edgar Link	unprocessable
sunshine_i10k-123122_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBFM
Sunshine Biopharma Inc. Stock $sbfm

2023 Q1 Form 10-K Financial Statement

#000168316823002128 Filed on April 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM Sunshine Biopharma Inc. Stock $sbfm

2023 Q1 Form 10-K Financial Statement

#000168316823002128 Filed on April 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBFM
Sunshine Biopharma Inc. Stock $sbfm